Abbott, Reata enter agreement to commercialize bardoxolone drug for CKD Abbott and Reata Pharmaceuticals today announced they have entered right into a collaboration contract to build up and commercialize bardoxolone methyl , which is currently in late Stage 2 trials for the treatment of chronic kidney disease http://www.edmdrx.com .S., excluding certain Asian marketplaces. Related StoriesAlport syndrome: an interview with Dr Paul Grint, CMO, RegulusKidney failure predictors in adolescents: an interview with Dr.D., senior vice president, pharmaceuticals, research and development, Abbott.’ Bardoxolone is an oral, first-in-class antioxidant irritation modulator that works by increasing the approximated glomerular filtration rate of the kidneys.
This article describes the first in-man study and therefore the first clinical program of the novel, intranasal, seasonal H1N1 influenza vaccine deltaFLU. The successful phase I study showed that the H1N1 vaccine was well safe and tolerated. Moreover, it proved that the deltaFLU influenza vaccination induces an immune response in the physical body. Another piece of very good news is normally that it was possible to demonstrate the induction of cross-protective immunity against additional influenza virus strains. The results of the medical phase I research are excellent. This vaccine guarantees optimum tolerance and safety.